ES2130622T3 - Sistema para la administracion transdermica de farmacos. - Google Patents

Sistema para la administracion transdermica de farmacos.

Info

Publication number
ES2130622T3
ES2130622T3 ES95922554T ES95922554T ES2130622T3 ES 2130622 T3 ES2130622 T3 ES 2130622T3 ES 95922554 T ES95922554 T ES 95922554T ES 95922554 T ES95922554 T ES 95922554T ES 2130622 T3 ES2130622 T3 ES 2130622T3
Authority
ES
Spain
Prior art keywords
therapeutic agent
pct
cyclodextrin
date jan
sec
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES95922554T
Other languages
English (en)
Inventor
Arto Olavi Urtti
Maria Riitta Sutinen
Timo Petteri Paronen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Application granted granted Critical
Publication of ES2130622T3 publication Critical patent/ES2130622T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7069—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained otherwise than by reactions only involving carbon to carbon unsaturated bonds, e.g. polysiloxane, polyesters, polyurethane, polyethylene oxide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nanotechnology (AREA)
  • Dermatology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Molecular Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biotechnology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

SISTEMA TRANSDERMICO DE LIBERACION CONTROLADA PARA EL ENVIO DE AL MENOS UN AGENTE TERAPEUTICO QUE INCLUYE: UN RESERVORIO QUE CONTIENE (A) EL AGENTE TERAPEUTICO DE FORMA IONIZADA Y (B) UN AGENTE AJUSTADOR DEL PH QUE CUANDO TOMA AGUA SE CONVIERTE EN UNA SOLUCION AMORTIGUANTE Y (C) UN POLISACARIDO EN FORMA CICLICA SELECCIONADO A PARTIR DE UN GRUPO INTEGRADO POR CICLODEXTRINA, DERIVADOS DE CICLODEXTRINA Y POLIMEROS DE CICLODEXTRINA, EL POLISACARIDO EN FORMA CICLICA ES CAPAZ DE MEJORAR LA SOLUBILIDAD DEL AGENTE TERAPEUTICO EN LA SOLUCION AMORTIGUANTE MEDIANTE LA FORMACION DE UN COMPLEJO DE INCLUSION CON EL AGENTE TERAPEUTICO; Y UNA PARED DEL RESERVORIO QUE INCLUYE UN POLIMERO SUSTANCIALMENTE IMPERMEABLE A LA FORMA IONIZADA O A LA FORMA COMPLEJA DE INCLUSION DEL AGENTE TERAPEUTICO PERO PERMEABLE AL AGUA Y A LA FORMA NO IONIZADA DEL AGENTE TERAPEUTICO. EL SISTEMA PERMITE LA LIBERACION DE UN AGENTE TERAPEUTICO QUE PUEDE SER UN ACIDO DEBIL O UNA BASE DE FORMA QUE MUESTRA MENOS VARIACION ENTRE LOS PACIENTES QUE LOS SISTEMAS YA EXISTENTES.
ES95922554T 1994-07-08 1995-06-20 Sistema para la administracion transdermica de farmacos. Expired - Lifetime ES2130622T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB9413866A GB2290964A (en) 1994-07-08 1994-07-08 Transdermal drug delivery system

Publications (1)

Publication Number Publication Date
ES2130622T3 true ES2130622T3 (es) 1999-07-01

Family

ID=10758074

Family Applications (1)

Application Number Title Priority Date Filing Date
ES95922554T Expired - Lifetime ES2130622T3 (es) 1994-07-08 1995-06-20 Sistema para la administracion transdermica de farmacos.

Country Status (12)

Country Link
US (1) US5817332A (es)
EP (1) EP0764020B1 (es)
JP (1) JP3734267B2 (es)
AT (1) ATE178485T1 (es)
AU (1) AU2740595A (es)
CA (1) CA2193129C (es)
DE (1) DE69508938T2 (es)
DK (1) DK0764020T3 (es)
ES (1) ES2130622T3 (es)
GB (1) GB2290964A (es)
GR (1) GR3030369T3 (es)
WO (1) WO1996001626A1 (es)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR19980033113A (ko) * 1996-10-25 1998-07-25 야스다케 히지 국소 마취제 수용액, 국소 마취제의 용해도를 개선시키는 방법, 신경독성이 감소된 국소 마취제 및 국소 마취제의 신경 독성을 감소시키는 방법
US6046177A (en) * 1997-05-05 2000-04-04 Cydex, Inc. Sulfoalkyl ether cyclodextrin based controlled release solid pharmaceutical formulations
DE19810951B4 (de) * 1998-03-13 2005-09-29 Ciba Speciality Chemicals Holding Inc. Verwendung eines textilen Materials als transdermales Abgabesystem sowie Verfahren zu seiner Herstellung
DE19814087A1 (de) * 1998-03-30 1999-10-14 Lohmann Therapie Syst Lts Feuchtigkeitsaktivierbares therapeutisches System
DE19814084B4 (de) 1998-03-30 2005-12-22 Lts Lohmann Therapie-Systeme Ag D2-Agonist enthaltendes transdermales therapeutisches System zur Behandlung des Parkinson-Syndroms und Verfahren zu seiner Herstellung
US6337328B1 (en) 1999-03-01 2002-01-08 Sepracor, Inc. Bupropion metabolites and methods of use
WO2001043775A2 (en) * 1999-12-16 2001-06-21 Dermatrends, Inc. Hydroxide-releasing agents as skin permeation enhancers
US6719997B2 (en) 2000-06-30 2004-04-13 Dermatrends, Inc. Transdermal administration of pharmacologically active amines using hydroxide-releasing agents as permeation enhancers
US6673363B2 (en) 1999-12-16 2004-01-06 Dermatrends, Inc. Transdermal and topical administration of local anesthetic agents using basic enhancers
US6582724B2 (en) * 1999-12-16 2003-06-24 Dermatrends, Inc. Dual enhancer composition for topical and transdermal drug delivery
US6586000B2 (en) 1999-12-16 2003-07-01 Dermatrends, Inc. Hydroxide-releasing agents as skin permeation enhancers
US20030104041A1 (en) * 1999-12-16 2003-06-05 Tsung-Min Hsu Transdermal and topical administration of drugs using basic permeation enhancers
US6689378B1 (en) 1999-12-28 2004-02-10 Kimberly-Clark Worldwide, Inc. Cyclodextrins covalently bound to polysaccharides
US7179483B2 (en) 2000-04-26 2007-02-20 Watson Pharmaceuticals, Inc. Compositions and methods for transdermal oxybutynin therapy
US20050227911A1 (en) * 2001-09-28 2005-10-13 Solubest Ltd. Hydrophilic dispersions of nanoparticles of inclusion complexes of macromolecules
US6878693B2 (en) * 2001-09-28 2005-04-12 Solubest Ltd. Hydrophilic complexes of lipophilic materials and an apparatus and method for their production
US20050233003A1 (en) * 2001-09-28 2005-10-20 Solubest Ltd. Hydrophilic dispersions of nanoparticles of inclusion complexes of salicylic acid
US7700851B2 (en) * 2001-11-13 2010-04-20 U.S. Smokeless Tobacco Company Tobacco nicotine demethylase genomic clone and uses thereof
US7759506B2 (en) 2002-02-25 2010-07-20 Diffusion Pharmaceuticals Llc Bipolar trans carotenoid salts and their uses
AU2003215396B2 (en) * 2002-02-25 2010-04-08 Diffusion Pharmaceuticals Llc Bipolar trans carotenoid salts and their uses
PL1629844T5 (pl) 2004-07-13 2012-10-31 Bayer Schering Pharma Oy Długoterminowy system dostarczania leku z kontrolowanym początkowym wyrzutem
CA2598882C (en) 2005-02-24 2020-02-25 Diffusion Pharmaceuticals Llc Trans carotenoids, their synthesis, formulation and uses
WO2006135785A2 (en) * 2005-06-10 2006-12-21 Medical College Of Georgia Research Institute Compositions and methods for treating immune disorders
US9446017B2 (en) 2005-08-11 2016-09-20 Augusta University Research Institute, Inc. Compositions and methods for treating herpes simplex virus
EP2004143A2 (en) * 2006-04-07 2008-12-24 Allergan, Inc. Compositions including relatively water insoluble/unwettable drugs and methods for using same
US9114133B2 (en) 2006-08-25 2015-08-25 U.S. Dept. Of Veterans Affairs Method of improving diastolic dysfunction
CA2683760C (en) 2007-04-13 2015-05-19 Diffusion Pharmaceuticals Llc Use of bipolar trans carotenoids as a pretreatment and in the treatment of peripheral vascular disease
MX2010004803A (es) 2007-10-31 2010-09-09 Diffusion Pharmaceuticals Llc Una nueva clase de composiciones terapeuticas que mejoran la difusion de moleculas pequeñas.
CN102458110A (zh) 2009-06-22 2012-05-16 扩散药品有限公司 扩散促进化合物及其单独或与溶栓药一起的应用
WO2011014775A1 (en) 2009-07-31 2011-02-03 The Brigham And Women's Hospital, Inc. Modulation of sgk1 expression in th17 cells to modulate th17-mediated immune responses
AU2011237592B2 (en) 2010-04-08 2016-10-27 Emory University Substituted androst-4-ene diones
CA2801292C (en) 2010-06-02 2019-01-22 Diffusion Pharmaceuticals Llc Oral formulations of bipolar trans carotenoids
US9585930B2 (en) 2011-03-20 2017-03-07 Trustees Of Boston University Therapeutic agent for emphysema and COPD
WO2012151474A2 (en) 2011-05-04 2012-11-08 Trustees Of Boston University Proton-motive force stimulation to potentiate aminoglycoside antibiotics against persistent bacteria
US20140227293A1 (en) 2011-06-30 2014-08-14 Trustees Of Boston University Method for controlling tumor growth, angiogenesis and metastasis using immunoglobulin containing and proline rich receptor-1 (igpr-1)
EP2543370A1 (en) 2011-07-06 2013-01-09 Georgia Health Sciences University Research Institute, Inc. Compositions and Methods for Treating Herpes Simplex Virus
US9243037B2 (en) 2011-11-10 2016-01-26 Trustees Of Boston College Gramicidin a mutants that function as antibiotics with improved solubility and reduced toxicity
US20150366890A1 (en) 2013-02-25 2015-12-24 Trustees Of Boston University Compositions and methods for treating fungal infections
EP3036226B1 (en) 2013-08-22 2020-01-08 The General Hospital Corporation Inhibitors of human 12/15-lipoxygenase
US11382883B2 (en) 2013-08-29 2022-07-12 Trustees Of Boston University Intermediate metabolism products to potentiate aminoglycoside antibiotics in bacterial infections
KR101948779B1 (ko) 2013-10-07 2019-05-21 테이코쿠 팔마 유에스에이, 인코포레이티드 덱스메데토미딘 경피 전달 장치 및 이의 사용 방법
CN110604728A (zh) * 2013-10-07 2019-12-24 帝国制药美国公司 用于管理疼痛的包含右旋美托咪啶经皮组合物的方法及组合物
US10987342B2 (en) 2013-10-07 2021-04-27 Teikoku Pharma Usa, Inc. Methods and compositions for transdermal delivery of a non-sedative amount of dexmedetomidine
JP6310070B2 (ja) 2013-10-07 2018-04-11 テイコク ファーマ ユーエスエー インコーポレーテッド デクスメデトミジン経皮組成物を用いる、注意欠陥多動性障害、不安症及び不眠症の治療法及び組成物
BR112016014404A2 (pt) * 2013-12-18 2017-08-08 Gnt Llc Composições e métodos para tratamento de glaucoma
JP6469587B2 (ja) 2013-12-18 2019-02-13 丸石製薬株式会社 含水型貼付剤
WO2016196664A1 (en) 2015-06-01 2016-12-08 Cedars-Sinai Medical Center Methods and use of compounds that bind to rela of nf-kb
EP3328856A2 (en) 2015-07-28 2018-06-06 Vyome Biosciences Pvt. Ltd. Antibacterial therapeutics and prophylactics
US10493049B2 (en) 2016-02-10 2019-12-03 Niracle LLC Applicator-based transdermal drug delivery system for administration of drugs in combination with topical formulations
KR20230014850A (ko) 2016-03-24 2023-01-30 디퓨젼 파마슈티컬즈 엘엘씨 암을 치료하기 위한, 화학 요법 및 방사선 요법과의 양극성 트랜스 카로티노이드의 용도
MX2019007923A (es) 2016-12-31 2019-09-10 Bioxcel Therapeutics Inc Uso de dexmedetomidina sublingual para el tratamiento de la agitacion.
WO2020006092A1 (en) 2018-06-27 2020-01-02 Bioxcel Therapeutics, Inc. Film formulations containing dexmedetomidine and methods of producing them
TWI772807B (zh) 2019-05-27 2022-08-01 日商救急藥品工業股份有限公司 外用製劑
WO2021016112A2 (en) 2019-07-19 2021-01-28 Bioxcel Therapeutics, Inc. Non-sedating dexmedetomidine treatment regimens
US11844753B2 (en) 2021-11-08 2023-12-19 Weiyong Li Transdermal drug delivery system for delivering a drug to a patient
US11806334B1 (en) 2023-01-12 2023-11-07 Bioxcel Therapeutics, Inc. Non-sedating dexmedetomidine treatment regimens

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4756710A (en) * 1985-04-05 1988-07-12 Merck & Co., Inc. pH-Mediated drug delivery system
US4749574A (en) * 1986-04-14 1988-06-07 Fujisawa Pharmaceutical Co., Ltd. Sustained-release transdermal delivery preparations
US4781924A (en) * 1987-11-09 1988-11-01 Alza Corporation Transdermal drug delivery device
SE8904296D0 (sv) * 1989-12-21 1989-12-21 Pharmacia Ab Transdermal system
HU210921B (en) * 1990-03-28 1995-09-28 Chinoin Gyogyszer Es Vegyeszet Process for preparing inclusion complexes of n-ethoxycarbonyl-3-morpholino-sydnonimine formed with cyclodextrines and pharmaceutical compositions containing them
GB9012663D0 (en) * 1990-06-07 1990-08-01 Erba Carlo Spa Galenic formulations containing cyclodextrins
GB9111732D0 (en) * 1991-05-31 1991-07-24 Orion Yhtymae Oy The use of certain salts of medetomidine and its optically active enantiomers to regulate the rate of transdermal administration of the drugs
US5518737A (en) * 1991-10-16 1996-05-21 Orion-Yhtyma Oy Peroral drug delivery system
US5324718A (en) * 1992-07-14 1994-06-28 Thorsteinn Loftsson Cyclodextrin/drug complexation

Also Published As

Publication number Publication date
GR3030369T3 (en) 1999-09-30
ATE178485T1 (de) 1999-04-15
JP3734267B2 (ja) 2006-01-11
CA2193129A1 (en) 1996-01-25
CA2193129C (en) 2007-11-06
WO1996001626A1 (en) 1996-01-25
US5817332A (en) 1998-10-06
GB2290964A (en) 1996-01-17
EP0764020A1 (en) 1997-03-26
DE69508938T2 (de) 1999-09-16
DE69508938D1 (de) 1999-05-12
AU2740595A (en) 1996-02-09
JPH10502388A (ja) 1998-03-03
DK0764020T3 (da) 1999-10-18
EP0764020B1 (en) 1999-04-07
GB9413866D0 (en) 1994-08-24

Similar Documents

Publication Publication Date Title
ES2130622T3 (es) Sistema para la administracion transdermica de farmacos.
ATE267798T1 (de) Kombinierte wirkstoffe als methode zur gezielten wirkstoff-freisetzung
ATE198152T1 (de) Oral anzuwendende arzneizubereitung mit verzögerter wirkstoffabgabe
TR200001998T1 (tr) Kontrollü salıverilen tolterodin uygulamak için ilaç formülasyonu
RS52577B (en) ONE-DAY OXYCODON FORMULATIONS
ATE298259T1 (de) Vorrichtung zur lokalen verabreichung einer arznei in einer körperhöhle
MEP28208A (en) Pharmaceutical formulations and use thereof in the prevention of stroke, diabetes and/or congestive heart failure
ES2130638T3 (es) Sistema para la liberacion de sustancia activa, filmogeno, vaporizable, para utilizar en las plantas.
ES2164040T1 (es) Uso de agonistas del sitio de union de la glicina o de inhibidores de la absorcion de la glicina para el tratamiento de trastornos neuropsiquiatricos.
ES2058111T3 (es) Composicion de liberacion controlada de dihidrocodeina.
ATE237330T1 (de) Verabreichung von nikotin im dickdarm zur behandlung von entzündlicher eingeweidenerkrankung
SE8703034D0 (sv) Oralt terapeutiskt system med systemisk verkan
CO5640120A2 (es) Formulacion y metodods para el tratamiento de trombocitemia
NZ501950A (en) Medicinal compositions for application to mucosa
ID28160A (id) Sistem pengobatan untuk pemberian fenilasetilglutamina, fenilasetilisoglutamina dan/atau fenilasetat.
KR950703972A (ko) 항혈전성 치료 및 암 예방을 위한 아세틸살리실산을 함유하는 경피 투여 시스템(transdermal administration system containing acetylsalicyliic acid for antithrombotic therapy and the prevention of cancer)
ATE388687T1 (de) Medikamentöse verabreichung von nikotin in form von kaugummi
EP0838225A3 (en) Aqueous local anesthetic solution
DK0856312T3 (da) Anvendelse af trospiumchlorid til fremstilling af et lægemiddel til behandling af blæresygdomme
HK1038310A1 (en) Compositions and methods for treating intracellular infections.
ATE135203T1 (de) System zur peroralen arzneimittelabgabe
HUP9903679A2 (hu) Olanzapin alkalmazása bipoláris zavar kezelésére szolgáló gyógyszerkészítmények előállítására
AR005724A1 (es) Derivados de ureido biologicamente activos utiles en el tratamiento de esclerosis multiple
SE9700617D0 (sv) New composition
FR2809958B1 (fr) Composition pharmaceutique sous forme liquide destinee a l'administration par voie orale d'un principe actif, ayant un gout desagreable, notamment un gout amer

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 764020

Country of ref document: ES